Tuesday, September 26, 2017 10:36:56 AM
"The process, advanced by Cannabics Pharmaceuticals, expands the firm’s proprietary know-how of personalization of CBD drug. The prevailing invention relates to a combined system and method for evaluating the sensitivity of a numerous of CBD-based treatment modalities on patient-based primary tumor biopsies and blood circulating tumor cells. This recent patent submission is a strong message and a dynamic reflection of the firm’s target: Cannabics products and methods will allow exquisitely accurate medical cannabis offerings to be applied into mainstream medical practice in the coming period".
Recent CNBX News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:27:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 03:13:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/14/2023 02:28:11 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM